vs
Prestige Consumer Healthcare Inc.（PBH）与WSFS FINANCIAL CORP（WSFS）财务数据对比。点击上方公司名可切换其他公司
Prestige Consumer Healthcare Inc.的季度营收约是WSFS FINANCIAL CORP的1.0倍（$283.4M vs $275.3M），WSFS FINANCIAL CORP净利率更高（31.5% vs 16.5%，领先15.1%），WSFS FINANCIAL CORP同比增速更快（7.5% vs -2.4%），过去两年WSFS FINANCIAL CORP的营收复合增速更高（1.7% vs 1.2%）
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
WSFS金融集团是一家金融服务企业，核心子公司WSFS银行是总部位于特拉华州及大特拉华谷地区规模最大、经营历史最久的本地管理银行与财富管理机构。集团共运营115个网点，其中88个为银行网点，分布在宾夕法尼亚、特拉华、新泽西、佛罗里达、弗吉尼亚、内华达六州，提供全面金融服务。
PBH vs WSFS — 直观对比
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $283.4M | $275.3M |
| 净利润 | $46.7M | $86.8M |
| 毛利率 | 55.5% | — |
| 营业利润率 | 29.1% | — |
| 净利率 | 16.5% | 31.5% |
| 营收同比 | -2.4% | 7.5% |
| 净利润同比 | -23.5% | 31.7% |
| 每股收益（稀释后） | $0.97 | $1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $275.3M | ||
| Q4 25 | $283.4M | $271.9M | ||
| Q3 25 | $274.1M | $270.5M | ||
| Q2 25 | $249.5M | $267.5M | ||
| Q1 25 | $296.5M | $256.1M | ||
| Q4 24 | $290.3M | $261.5M | ||
| Q3 24 | $283.8M | $267.7M | ||
| Q2 24 | $267.1M | $266.0M |
| Q1 26 | — | $86.8M | ||
| Q4 25 | $46.7M | $72.7M | ||
| Q3 25 | $42.2M | $76.4M | ||
| Q2 25 | $47.5M | $72.3M | ||
| Q1 25 | $50.1M | $65.9M | ||
| Q4 24 | $61.0M | $64.2M | ||
| Q3 24 | $54.4M | $64.4M | ||
| Q2 24 | $49.1M | $69.3M |
| Q1 26 | — | — | ||
| Q4 25 | 55.5% | — | ||
| Q3 25 | 55.3% | — | ||
| Q2 25 | 56.2% | — | ||
| Q1 25 | 57.3% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 55.5% | — | ||
| Q2 24 | 54.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 29.1% | 35.8% | ||
| Q3 25 | 29.1% | 37.3% | ||
| Q2 25 | 28.8% | 35.7% | ||
| Q1 25 | 29.8% | 34.0% | ||
| Q4 24 | 31.7% | 32.3% | ||
| Q3 24 | 29.7% | 31.9% | ||
| Q2 24 | 27.0% | 34.0% |
| Q1 26 | — | 31.5% | ||
| Q4 25 | 16.5% | 26.7% | ||
| Q3 25 | 15.4% | 28.3% | ||
| Q2 25 | 19.0% | 27.0% | ||
| Q1 25 | 16.9% | 25.7% | ||
| Q4 24 | 21.0% | 24.6% | ||
| Q3 24 | 19.2% | 24.1% | ||
| Q2 24 | 18.4% | 26.0% |
| Q1 26 | — | $1.64 | ||
| Q4 25 | $0.97 | $1.33 | ||
| Q3 25 | $0.86 | $1.37 | ||
| Q2 25 | $0.95 | $1.27 | ||
| Q1 25 | $1.00 | $1.12 | ||
| Q4 24 | $1.22 | $1.08 | ||
| Q3 24 | $1.09 | $1.08 | ||
| Q2 24 | $0.98 | $1.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $62.4M | — |
| 总债务越低越好 | $1.0B | — |
| 股东权益账面价值 | $1.8B | $2.7B |
| 总资产 | $3.5B | $22.1B |
| 负债/权益比越低杠杆越低 | 0.56× | — |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $62.4M | $1.7B | ||
| Q3 25 | $119.1M | — | ||
| Q2 25 | $139.5M | — | ||
| Q1 25 | $97.9M | — | ||
| Q4 24 | $50.9M | $1.2B | ||
| Q3 24 | $51.5M | — | ||
| Q2 24 | $34.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $993.1M | — | ||
| Q2 25 | $992.7M | — | ||
| Q1 25 | $992.4M | — | ||
| Q4 24 | $992.0M | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — |
| Q1 26 | — | $2.7B | ||
| Q4 25 | $1.8B | $2.7B | ||
| Q3 25 | $1.8B | $2.8B | ||
| Q2 25 | $1.9B | $2.7B | ||
| Q1 25 | $1.8B | $2.7B | ||
| Q4 24 | $1.8B | $2.6B | ||
| Q3 24 | $1.7B | $2.7B | ||
| Q2 24 | $1.7B | $2.5B |
| Q1 26 | — | $22.1B | ||
| Q4 25 | $3.5B | $21.3B | ||
| Q3 25 | $3.4B | $20.8B | ||
| Q2 25 | $3.4B | $20.8B | ||
| Q1 25 | $3.4B | $20.5B | ||
| Q4 24 | $3.3B | $20.8B | ||
| Q3 24 | $3.3B | $20.9B | ||
| Q2 24 | $3.3B | $20.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.54× | — | ||
| Q4 24 | 0.55× | — | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.65× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $78.3M | — |
| 自由现金流经营现金流 - 资本支出 | $75.3M | — |
| 自由现金流率自由现金流/营收 | 26.6% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 1.68× | — |
| 过去12个月自由现金流最近4个季度 | $267.2M | — |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $78.3M | $220.0M | ||
| Q3 25 | $57.5M | $121.5M | ||
| Q2 25 | $79.0M | $37.2M | ||
| Q1 25 | $61.8M | $8.7M | ||
| Q4 24 | $65.1M | $219.9M | ||
| Q3 24 | $69.8M | $3.1M | ||
| Q2 24 | $54.8M | $44.8M |
| Q1 26 | — | — | ||
| Q4 25 | $75.3M | $213.6M | ||
| Q3 25 | $55.4M | $120.3M | ||
| Q2 25 | $78.2M | $35.2M | ||
| Q1 25 | $58.4M | $6.3M | ||
| Q4 24 | $63.5M | $205.6M | ||
| Q3 24 | $67.8M | $-489.0K | ||
| Q2 24 | $53.6M | $42.1M |
| Q1 26 | — | — | ||
| Q4 25 | 26.6% | 78.6% | ||
| Q3 25 | 20.2% | 44.5% | ||
| Q2 25 | 31.3% | 13.2% | ||
| Q1 25 | 19.7% | 2.5% | ||
| Q4 24 | 21.9% | 78.6% | ||
| Q3 24 | 23.9% | -0.2% | ||
| Q2 24 | 20.1% | 15.8% |
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 2.3% | ||
| Q3 25 | 0.8% | 0.5% | ||
| Q2 25 | 0.3% | 0.7% | ||
| Q1 25 | 1.2% | 0.9% | ||
| Q4 24 | 0.5% | 5.5% | ||
| Q3 24 | 0.7% | 1.4% | ||
| Q2 24 | 0.4% | 1.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.68× | 3.03× | ||
| Q3 25 | 1.36× | 1.59× | ||
| Q2 25 | 1.66× | 0.51× | ||
| Q1 25 | 1.23× | 0.13× | ||
| Q4 24 | 1.07× | 3.43× | ||
| Q3 24 | 1.28× | 0.05× | ||
| Q2 24 | 1.12× | 0.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
WSFS
暂无分部数据
